Micropenis Medication: Testosterone, hCG, and DHT Options

Hormonal medication is the first-line treatment for micropenis, and the most commonly used drugs are testosterone (given as injections or applied to the skin), dihydrotestosterone cream, and human chorionic gonadotropin (hCG). These treatments work best when started in infancy or childhood, though they can still produce measurable gains in older children and adolescents. The picture is more complicated for adults, where hormonal therapy alone rarely brings penile length into the normal range, and the question of what counts as a realistic outcome depends heavily on when treatment begins and what caused the condition in the first place.

What Micropenis Actually Means

Micropenis is a clinical diagnosis, not a casual label. It refers to a stretched penile length that falls at least 2.5 standard deviations below the average for a person’s age.¹ In a newborn, that typically means a stretched length under about 1.9 centimeters. The penis itself is structurally normal in most cases, with a properly formed urethra and erectile tissue; it is simply unusually small because something went wrong with the hormonal signals that drive penile growth before birth.

The most common underlying cause is a shortage of testosterone during fetal development. That shortage can stem from problems with the brain’s signaling to the testes (a condition called hypogonadotropic hypogonadism) or from the testes themselves failing to produce enough hormone.² Less frequently, the issue is not low testosterone but the body’s inability to respond to it normally, a situation known as partial androgen insensitivity. Identifying which category a patient falls into matters enormously, because it shapes which medication will work and how much growth to expect.

One thing clinicians check for early on is whether the penis is truly small or just hidden. Prepubertal boys who carry extra weight around the pubic area sometimes appear to have a micropenis when the shaft is actually buried beneath a pad of fat.³ Pressing back the surrounding tissue reveals normal penile structure. No medication is needed in those cases, and confusing a buried penis with true micropenis can lead to unnecessary hormonal treatment.

Testosterone Therapy in Children

Testosterone is the medication with the longest track record for micropenis. In children, it is most often given as a short course of intramuscular injections of testosterone enanthate, typically three monthly doses. One study of children treated with hormonal therapy found that stretched penile length more than doubled in boys older than eleven, rising from about 26 millimeters to roughly 64 millimeters.⁴ Younger children in the same study also showed strong gains, going from around 15 millimeters to 37 millimeters. These results typically bring the measurement closer to or within the normal range for the child’s age group.

The growth response is encouraging, but there is a timing nuance that parents should be aware of. Animal research has shown that exposing the penis to androgens very early in life can cause a burst of growth followed by a plateau, ultimately resulting in a smaller adult size than if treatment had been delayed slightly.⁵ A comprehensive review recommended that hormonal therapy ideally begin after the age of six months, once the natural hormone surge of “mini-puberty” has passed.⁶ Starting after that window appears to preserve the penis’s ability to respond to testosterone later, during true puberty, rather than burning through that responsiveness too soon.

How hCG Works Differently

Human chorionic gonadotropin takes an indirect route. Instead of supplying testosterone from outside, hCG stimulates the testes to produce their own testosterone. This makes it especially useful when the problem lies upstream in the brain’s hormonal signaling rather than in the testes themselves. In patients with hypogonadotropic hypogonadism treated with hCG, stretched penile length increased from about 5.4 centimeters to roughly 7.5 centimeters over a course of treatment, while testicular volume also grew.⁷ That testicular growth is a meaningful bonus: it suggests the drug is waking up the entire reproductive axis, not just forcing penile tissue to stretch.

In neonates, even a brief hCG protocol can produce rapid results. A study of six newborns with ambiguous genitalia found that three daily injections led to measurable penile growth within five days, with four of the six reaching a normal penile length by 48 hours after the final dose.⁸ Beyond the size gain, the short course served a diagnostic purpose: a penis that responds to hCG confirms the testes are functional and that the tissue can react to androgens, which helps guide future management.

A more intensive approach uses continuous infusion of recombinant gonadotropins. In infants with congenital hypogonadotropic hypogonadism treated this way, stretched penile length roughly tripled, going from about 14 millimeters to around 43 millimeters, and micropenis was corrected in all but one patient.⁹ Inhibin B and anti-Müllerian hormone also rose, indicating the treatment was activating testicular cells beyond just the ones that make testosterone.

Dihydrotestosterone Cream and How It Compares

Dihydrotestosterone is a more potent androgen than testosterone, and it does not need to be converted by the body before acting on tissue. Topical DHT gel applied directly to the penis has been studied as an alternative to testosterone injections, with the advantage of being non-invasive and easy for parents to administer at home. A randomized study comparing transdermal DHT with injectable testosterone enanthate in boys with idiopathic micropenis found that DHT produced a significantly larger gain: an average increase of about 2.4 centimeters compared to roughly 1.8 centimeters with testosterone injections.¹⁰ Both treatments brought the average penile length within about 0.7 standard deviations of the mean, well out of the micropenis range.

DHT may also be helpful in cases where partial androgen insensitivity is complicating the picture. In a case series of patients with confirmed partial androgen insensitivity syndrome, topical DHT produced a 40 percent gain in stretched penile length in a prepubertal patient and a 63 percent gain in a peripubertal patient.¹¹ However, the same case series found that an adult patient who had already undergone a year of high-dose weekly testosterone showed no additional growth from DHT. That finding underscores a recurring theme: the earlier the treatment, the better the response. Once the growth window has closed, adding another androgen on top often produces diminishing returns.

When Androgen Insensitivity Muddies the Picture

Not every micropenis case responds predictably to hormone therapy, and sometimes the reason comes down to the androgen receptor itself. Partial androgen insensitivity syndrome is caused by mutations in the gene encoding the androgen receptor, which means that even when testosterone levels are adequate, the body’s tissues do not respond to the hormone as strongly as they should. In some patients, the insensitivity is mild enough that flooding the system with extra androgens can still push past the resistance and produce growth.¹² In others, the receptor mutation is severe enough that exogenous androgens have little effect.

This is why a poor response to testosterone or DHT is itself diagnostically informative. If a child’s penis does not grow after a standard course of testosterone, clinicians typically investigate for receptor mutations. In one reported case, a patient showed a good initial response to exogenous androgens, but genetic testing still revealed an androgen receptor mutation, illustrating that the relationship between receptor function and clinical response is not black-and-white. Some degree of resistance can coexist with a meaningful treatment response, especially if the mutation only partially impairs receptor binding.

Hormonal Medication Before Surgery

Even when surgery is on the table, hormonal medication often plays an important preparatory role. Many boys with micropenis also have hypospadias, a condition where the urethral opening is in the wrong position on the penis, requiring surgical correction. Operating on very small tissue is technically harder and comes with higher complication rates. A short course of testosterone before surgery increases penile length and, just as importantly, enlarges the glans, giving the surgeon more tissue to work with.

In one study, three monthly injections of testosterone enanthate increased penile length from about 20 millimeters to roughly 24 millimeters and glans circumference from about 27 millimeters to nearly 38 millimeters, with no apparent side effects.¹³ That extra tissue can make the difference between a straightforward repair and one plagued by healing problems. Androgen stimulation also increases the number and density of blood vessels in penile tissue, which improves wound healing after the operation.¹⁴

Timing between the hormonal course and the surgery matters. A study examining preoperative topical androgen treatment found that both protocols tested produced a significant, sustained increase in glans width, but that delaying surgery more than three months after finishing the androgen course may undo some of the vascular benefits.¹⁵ So clinicians aim to schedule the procedure within a few months of completing the hormone course.

What About Adults

The elephant in the room for anyone reading about micropenis medication as an adult is whether these treatments still work once growth plates have fused and puberty is long over. The honest answer is that the evidence is thin and the results are modest at best. The DHT case series mentioned earlier found zero additional growth in an adult who had already received high-dose testosterone for a year.¹⁶ A review of the literature concluded that there is no known medical intervention, apart from phalloplasty, that can guarantee a normal-sized penis in adulthood.¹⁷

That said, “no guarantee of normal size” does not mean hormonal therapy is useless for adults in all situations. Men with untreated hypogonadism who have never received adequate testosterone may still see some growth if the tissue retains residual androgen sensitivity. The gains tend to be smaller than what children experience, and they may not close the gap entirely, but for someone starting with a stretched length well below two standard deviations, even a centimeter of growth can be psychologically meaningful. The trouble is that no large trial has rigorously tested adult testosterone or DHT therapy specifically for micropenis, so the evidence consists mostly of case reports and small series.

Long-Term Outcomes and Quality of Life

A long-term follow-up of men with congenital micropenis treated with testosterone from infancy or childhood found that adult penile length remained below the normal mean in all subjects, even among those who had responded well to treatment earlier in life.¹⁸ All men in the study reported functional erections, but half expressed dissatisfaction with the appearance of their genitalia. Dissatisfaction with body image was driven not only by penile size but also by related features like sparse body hair and a youthful appearance, suggesting that the cosmetic concerns often extend beyond the penis itself in men with conditions affecting the entire hormonal axis.

An earlier study of eight men with micropenis from hypogonadotropic hypogonadism, treated with testosterone from infancy or childhood through to maturity, provided context for what medication can and cannot do over a lifetime.¹⁹ The data reinforced the view that early hormonal intervention sets the trajectory for later growth but does not erase the size difference entirely. Psychological support is consistently recommended as part of ongoing management, because the gap between expectations and reality can take a toll on self-image and relationships regardless of functional sexual outcomes.²⁰

Environmental Factors and Prevention

While medications treat micropenis after it develops, there is growing interest in whether some cases could be prevented by reducing exposure to endocrine-disrupting chemicals during pregnancy. Phthalates, a class of chemicals found in plastics, food packaging, and personal care products, have been linked to disrupted male genital development in utero. A study found that maternal phthalate exposure can adversely affect penile growth during fetal development.²¹ The mechanism is thought to involve interference with the fetal testosterone surge that normally occurs mid-pregnancy and drives penile elongation.

This line of research is still developing, and no one is claiming that all micropenis cases are caused by chemical exposure. Most are driven by genetic conditions or problems with the hormonal axis that would occur regardless of environmental factors. Still, for pregnant individuals, minimizing exposure to known endocrine disruptors is a reasonable precaution that aligns with broader reproductive health guidance. It would not eliminate micropenis as a clinical entity, but it might reduce the proportion of cases that have an environmental component.

Predicting Who Will Respond to Treatment

One of the more frustrating aspects of micropenis management is the variability in treatment response. Two children with seemingly identical presentations can have very different outcomes on the same medication regimen. Research has been trying to identify clinical predictors that might help set expectations. A retrospective study examining penile morphology and hormonal factors found no single overwhelming predictor of response, and treatment initiated during mini-puberty was not substantially more effective than treatment started slightly later.²²

What does seem to matter is the underlying cause. Boys whose micropenis stems from hypogonadotropic hypogonadism tend to respond well to both testosterone and hCG, because their penile tissue is structurally normal and simply needs the hormonal signal it missed. Those with androgen receptor mutations have more variable outcomes, as described earlier. And boys with certain syndromic conditions that affect multiple organ systems may have tissue-level abnormalities that limit how much the penis can grow regardless of the hormonal environment. A short trial of testosterone or hCG early on often serves double duty, both treating the condition and revealing how responsive the tissue is, which in turn guides whether more aggressive hormonal therapy, watchful waiting through puberty, or eventual surgical planning is the right next step.